{
    "clinical_study": {
        "@rank": "147972", 
        "acronym": "levobupi", 
        "arm_group": [
            {
                "arm_group_label": "Levo-7.5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage:  7.5 mg. Single Dose."
            }, 
            {
                "arm_group_label": "Levo-9.37", 
                "arm_group_type": "Experimental", 
                "description": "Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage:  9.37 mg. Single Dose."
            }, 
            {
                "arm_group_label": "Levo-11.25", 
                "arm_group_type": "Active Comparator", 
                "description": "Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage:  11.25 mg. Single Dose."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate motor block probability throughout time and\n      clinical profile when using three different doses of HLBP 0.75% (7.5, 9.37 and 11.25 mg) by\n      a unilateral spinal block technique."
        }, 
        "brief_title": "Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy", 
        "completion_date": {
            "#text": "July 2010", 
            "@type": "Actual"
        }, 
        "condition": [
            "Disorder of Knee", 
            "Anesthesia"
        ], 
        "detailed_description": {
            "textblock": "Previous IRB approval and informed consent, 180 ASA I-II adults under ambulatory knee\n      arthroscopy will be randomly allocated to receive unilateral spinal anesthesia with 7.5\n      (group Levo-7.5, n=59), 9.37(group Levo-9.37, n=61) and 11.25 (group Levo-11.25, n=60) mg of\n      HLBP 0.75% using a 27-gauge Whitacre needle at a rate of 0.1 ml/ seg. and lateral decubitus\n      position maintained for 5 min after injection.\n\n      An independent observer will evaluate motor (modified Bromage scale) and sensory\n      (transcutaneal electrical stimulation at T10, L1, L3, and S1 dermal segments) levels and\n      presence of adverse events immediately after return to supine, at the end of surgery and\n      each 10 min from admission to PACU until home discharge conditions.\n\n      Trans-cutaneal electrical stimulation (TES) will be made with a PNS (Ministim\u00ae model MS- IV,\n      Organon, Dublin, Irland) using 50-Hz tetanus stimuli for 5 seg. from 10 to 60 mA 3,4."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 18-64 y.o. scheduled for knee arthroscopy (therapeutic or diagnostic)\n\n        Exclusion Criteria:\n\n          -  Cardiac or pulmonary disease\n\n          -  Antiplatelet or anticoagulant drugs use during 7 days before surgery\n\n          -  History of coagulative disorders\n\n          -  Bilateral procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881087", 
            "org_study_id": "LevoBupi-003"
        }, 
        "intervention": {
            "arm_group_label": [
                "Levo-7.5 mg", 
                "Levo-9.37", 
                "Levo-11.25"
            ], 
            "description": "Each 4 ml of the administred solution contains:  Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.", 
            "intervention_name": "Hyperbaric Levobupivacaine 0.75%", 
            "intervention_type": "Drug", 
            "other_name": "Bupinest 0.75% Pesado"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Levobupivacaine", 
                "Bupivacaine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Knee Arthroscopy", 
            "Levobupivacaine", 
            "Spinal Anesthesia", 
            "Motor Block"
        ], 
        "lastchanged_date": "June 19, 2013", 
        "link": {
            "description": "http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=90150010&pident_usuario=0&pcontactid=&pident_revista=341&ty=7&accion=L&origen=reuma%20&web=http://www.revcolanest.com.co&lan=es&fichero=341v38n04a90150010pdf001.pdf", 
            "url": "http://www.redalyc.org/articulo.oa?id=195119002005"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Cali", 
                    "country": "Colombia", 
                    "state": "Valle del Cauca", 
                    "zip": "76001000"
                }, 
                "name": "Fundaci\u00f3n Valle del Lili"
            }
        }, 
        "location_countries": {
            "country": "Colombia"
        }, 
        "number_of_arms": "3", 
        "official_title": "Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy: A Double Blind, Randomized Clinical Trial Comparing Three Low Doses", 
        "overall_official": [
            {
                "affiliation": "Fundaci\u00f3n Valle del Lili", 
                "last_name": "Fredy J Ariza, MD., MSc.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Unidad de Investigaciones Cl\u00ednicas, Fundaci\u00f3n Valle del Lili", 
                "last_name": "Marisol Badiel, MD., MSc.", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Likelihood Rate of motor block persistence after a dosis of spinal HLBP 0.75%", 
            "measure": "Probability of motor block", 
            "safety_issue": "No", 
            "time_frame": "200 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881087"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fundacion Clinica Valle del Lili", 
            "investigator_full_name": "Fredy Ariza", 
            "investigator_title": "Anesthesiologist, Epidemiologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Failed Spinal Block Rate for each treatment group", 
            "measure": "Failed Spinal Block Rate", 
            "safety_issue": "Yes", 
            "time_frame": "15 minutes after dose"
        }, 
        "source": "Fundacion Clinica Valle del Lili", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundacion Clinica Valle del Lili", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}